ALZHEIMER'S THERAPY

Referral Form



Patient Demographic Information				(Or Attach Face Sheet from Patient Chart)				
Patient Name	DOB		Gender	Male 🗌	Female 🗌	Weight	lbs 🗌 kg 🔲	
SSN Phone	/	Allergies						
Address	C	City		State		Zip Code		
Patient Status New to Therapy	Con	tinuing Tl	herapy	Next Tre	eatment Date	e		
Patient Insurance Information (Or Attach Copies of Patient's Insurance Card)								
Primary Insurance	Name of the Insured			Relationship				
Member ID#	Group #	ŧ		Insura	ance Phone #	ŧ		
Secondary Rx Carrier			Rx ID #	‡	Rx C	Group #		
Medical Information								
 Other Alzheimer's Disease (ICD-10 code: G30.8) Alzheimer's Disease, unspecified (ICD-10 code: G30.9) Mild cognitive impairment, so stated (ICD-10 code: G31.84) -AND- Encounter for clinical registry program (ICD-10 code: Z00.6),Medicare required 								
Therapy Orders								
 Leqembi: 10mg/kg IV every 2 weeks (lecanemab) MRIs should be performed at baseline & prior to the 5th, 7th, and 14th infusion HOLD infusion if MRI is not performed at indicated interval 								
Kisunla: 700mg IV every 4 week for 3 doses, then 1400mg IV every 4weeks thereafter (donanemab)								
Maintenance: 1400mg IV every 4 weeks								
 MRIs should be performed at baseline & prior to the 2nd, 3rd, 4th, and 7th infusion HOLD infusion if MRI is not performed at indicated interval 								
Refill for: 🗌 6 months 🔲 1 year 🗋 Other:								
Additional orders: Lab orders:								

ALZHEIMER'S THERAPY



Required Documentation For Referral Processing & Insurance Approval								
 Include signed and completed order (MD/prescriber to complete page 1) Include patient demographic information and insurance information Include patient's medication list Supporting clinical notes (H&P) to support primary diagnosis Other medical necessity:								
Required								
Patient enrolled in the CMS National Patient Registry (Medicare & Medicare Advantage required)								
Issue number: Date of registry enrollment:								
Provide copy of CMS national patient registry confirmation								
Confirmed presence of amyloid pathology								
Attach results: Amyloid PET scan OR +CSF (cerebrospinal fluid)								
☐ MRI of the brain (within 1 year) - attach results ☐ Cognitive assessment scores (list all available, attach results):								
MMSE: Score Date of assessment								
MoCA: Score Date of assessment								
CDR: Score Memory box: Score Date of assessment								
Other: Score Date of assessment								
Functional assessment score: (attach results) Assessment Name: FAQ FAST Other: Assessment date:								
Include labs and/or test results for the following:								
Genotype testing for ApoE4 -OR-								
ApoE4 genetic testing has NOT been completed. Provider has counselled thepatient on how testing for ApoE4 status informs the risk of developing ARIA and the patient has shared decision-making to initiate Leqembi								
Does the patient have objective impairment in episodic memory as evidenced by a memory test (i.e., Free and Cued, Wechsler, etc.)? (BCBS required) Yes No								
Is the patient on therapeutic anticoagulation/antiplatelet therapy? Yes 🗌 No								
If yes, please note therapy and dose:If yes, please note therapy and dose:								
Prescriber Insurance Information								
Prescriber Name NPI# Office # Fax #								
Address City State Zip Code								
I Authorize DeliverIt specialty pharmacy to initiate Prior Authorizations on my behalf. Date								
DAW (Dispense as written). Prescriber's Signature								
Prescriber certifies that this referral form contains an original signature and is signed by the treating prescriber. No stamped signatures will be accepted. Where required by law, send electronic prescription or on official state prescription blank. In the event requested agent is not available through DeliverIt Group, this prescription shall be forwarded to an eligible pharmacy.								